Home › Funds › EULAV Asset Management › MDGL
EULAV Asset Management position in MDGL
MADRIGAL PHARMACEUTICALS INC · Health Care
EULAV Asset Management reported holding 51,000 shares of MDGL (MADRIGAL PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$25.7M, representing 0.93% of its reported portfolio and ranking #38 among its reported holdings. EULAV Asset Management has disclosed MDGL holdings in 12 of the last 12 reported quarters, going back to Q4 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How EULAV Asset Management's MDGL position evolved
EULAV Asset Management first disclosed a stake in MDGL in Q4 2023 at 13,000 shares (US$3.0M). The position peaked in Q4 2025 at 49,000 shares, worth US$28.5M. Across 12 filings, EULAV Asset Management increased the stake 3 time(s), trimmed it 4 time(s) and left it unchanged 4 time(s). The most recent filing (Q3 2026) shows 51,000 shares valued at US$25.7M — a reduction of -1,000 shares quarter over quarter.. Notable position changes include a 210% increase in Q2 2025 (shares rose 52% over the following quarter), a 65% increase in Q3 2025 (shares rose 27% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2023 | 13.00K | $3.01M | New |
| Q1 2024 | 11.00K | $2.94M | Reduce |
| Q2 2024 | 10.00K | $2.80M | Reduce |
| Q3 2024 | 10.00K | $2.12M | Hold |
| Q4 2024 | 10.00K | $3.09M | Hold |
| Q1 2025 | 10.00K | $3.31M | Hold |
| Q2 2025 | 31.00K | $9.38M | Add |
| Q3 2025 | 51.00K | $23.39M | Add |
| Q4 2025 | 49.00K | $28.53M | Reduce |
| Q1 2026 | 49.00K | $25.65M | Hold |
| Q2 2026 | 52.00K | $27.92M | Add |
| Q3 2026 | 51.00K | $25.70M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About MDGL and 13F data
MDGL (MADRIGAL PHARMACEUTICALS INC) is a Health Care company. 45 other funds we track also report a position in MDGL — the largest reported positions include BAKER BROS. ADVISORS LP (US$1.15B), RTW INVESTMENTS, LP (US$1.07B), Janus Henderson Group (US$1.05B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding MDGL
- BAKER BROS. ADVISORS LP 2.14M sh · $1.15B · Q2 2026
- RTW INVESTMENTS, LP 1.99M sh · $1.07B · Q2 2026
- Janus Henderson Group 2.02M sh · $1.05B · Q1 2026
- Jupiter Topco LLC 1.94M sh · $1.04B · Q2 2026
- Avoro Capital Advisors LLC 1.83M sh · $984.41M · Q2 2026
- Paulson & Co 1.34M sh · $719.52M · Q2 2026
- PAULSON & CO. INC. 1.34M sh · $719.52M · Q2 2026
- WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC 337.04K sh · $169.85M · Q3 2026
- ARMISTICE CAPITAL, LLC 288.00K sh · $154.64M · Q2 2026
- Rock Springs Capital Management LP 175.00K sh · $93.97M · Q2 2026
More on EULAV Asset Management
FAQ
How long has EULAV Asset Management held MDGL?
EULAV Asset Management has disclosed MDGL holdings in 12 of the last 12 reported quarters, going back to Q4 2023.
What is EULAV Asset Management's current position in MDGL?
As of Q3 2026, EULAV Asset Management holds 51.00K shares of MDGL (MADRIGAL PHARMACEUTICALS INC), valued at $25.70M, representing 0.93% of its reported portfolio and ranking #38.
Has EULAV Asset Management been buying or selling MDGL?
In the latest 13F filing (Q3 2026), EULAV Asset Management reduced its position in MDGL. The position peaked in Q4 2025 at 49.00K shares.
Which other funds hold MDGL?
Other major institutional holders of MDGL include BAKER BROS. ADVISORS LP, RTW INVESTMENTS, LP, Janus Henderson Group, among 45 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.